Researchers at Inventisbio Co. Ltd. and Inventisbio LLC have described Werner syndrome ATP-dependent helicase (WRN; RECQ3; RECQL2) inhibitors reported to be useful for the treatment of cancer.
Scientists at Beigene Ltd. and Beigene Switzerland GmbH have identified phosphatidylinositol 3-kinase α (PI3Kα) (H1047R mutant) inhibitors reported to be useful for the treatment of cancer, congenital lipomatous overgrowth, vascular malformations, epidermal naevi and skeletal abnormalities and PIK3CA related overgrowth spectrum (PROS).
Researchers have described the development of a novel murine model of glioblastoma established with a patient-derived xenograft (PDX) in humanized mice that harbored an almost complete human immune microenvironment.
Researchers from the University of Connecticut have worked in the development of a collection of propargyl-linked antifolate (PLA) chemotypes for infectious pathogens with different functionalities, including potential anti-cancer, anti-inflammatory and anti-infection activities.
Medigene AG has announced the selection of KRAS G12V, in the context of HLA*A11, as the initial target for the co-development of T-cell receptor-guided T-cell engagers (TCR-TCEs) with Wuxi Biologics Co. Ltd.
Base Therapeutics (Shanghai) Co. Ltd.’s NK-510 cell injection, a zero-off-target base-edited natural killer (NK) cell product, has received approvals to start clinical trials from both the U.S. FDA and China’s NMPA for clinical trials for advanced solid tumors.
RSS
